While investors will be keeping a close eye on the 48-week read-out of the Phase II trial of Summit Therapeutics’ utrophin modulator ezutromid in patients with Duchenne muscular dystrophy, expected in the third quarter, the Oxford, UK-based biotech is increasing its interest in novel antibiotics. Company CEO Glyn Edwards caught up with Scrip at the 2018 Biotech Showcase and outlined how Summit intends to take on both DMD and develop narrow spectrum antibiotics against new targets in challenging pathogens such as Clostridium difficile.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.
The German group is paying $3.9bn to get hold of the US firm and its two approved products.
After dropping its lead program in December, Spruce has been exploring strategic options – and thinks it has a de-risked path for MPS IIIB therapy tralesinidase from BioMarin.
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
